UK's Oxford Biomedica falls as H1 operating loss widens

** Shares of cell and gene therapy developer Oxford Biomedica OXB.L down 1.94% at 456p

** Reports H1 operating loss of £29.1 mln ($38.87 mln), vs a £23.6 mln loss in the same period last year

** Says continued group revenue growth was offset by a £7.6 mln impairment of France property, plant and equipment

** Management remains confident in long-term growth potential in France

** Stock down about 26% YTD

($1 = 0.7486 pounds)